By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
    • Life Style
  • News
  • Technology
  • Travel
  • Videos
Reading: Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • News
  • Technology
  • Travel
  • Videos
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
    • Life Style
  • News
  • Technology
  • Travel
  • Videos
Follow US
Adkhabar > Blog > News > Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech
Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech
News

Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech

Last updated: 23/09/2025 7:36 PM
Published: 23/09/2025
Share
SHARE

Specializing in enzymes and fermentation, the biotech company will transform the expansion of Kemin’s global enzyme production capabilities

- Advertisement -

DES MOINES, Iowa and SHANGHAI, Sept. 23, 2025 /PRNewswire/ — Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, is pleased to announce its acquisition of CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio. This strategic move strengthens Kemin’s position as a global leader in enzyme innovation for markets such as animal feed, food, aquaculture, textiles, paper and pulp, and biofuel industries.

- Advertisement -

With this acquisition, Kemin has full ownership of CJ Youtell’s fermentation plants and its enzyme product portfolio. CJ Youtell brings to Kemin a world-class fermentation platform, including strategically located plants in Shandong and Hunan, China. These newly integrated assets will expand Kemin’s enzymes business, enabling the delivery of high-performance, sustainable enzyme technologies directly to customers worldwide.

- Advertisement -

“We are pleased to welcome CJ Youtell into the Kemin family,” said Dr. Chris Nelson, President and CEO, Kemin Industries. “This acquisition is a bold step forward in our ongoing strategy to provide cutting-edge fermentation solutions directly to our customers. Adding CJ Youtell to our portfolio further enhances Kemin’s expertise and dedication to supply high-quality and innovative enzyme ingredients and solutions across industries and around the world.”

- Advertisement -

The addition of the new facilities in China supports Kemin’s growth in R&D with laboratories and technical teams specializing in bioengineering, biochemistry, and enzyme formulation. With product innovation, manufacturing efficiencies, and the delivery of high-quality finished products, Kemin will be able to optimize production costs, reduce supply chain risk, and offer competitively priced, high-quality enzyme solutions across multiple markets and industries.

- Advertisement -

“The acquisition of CJ Youtell marks a powerful expansion of Kemin’s enzyme capabilities,” said Michelle Lim, President, Kemin Enzymes. “For over 40 years, Kemin has been formulating and delivering enzyme solutions across multiple markets and industries. With CJ Youtell’s fermentation expertise now part of our portfolio, we offer customers a fully integrated solution—from proprietary strain development and manufacturing to final formulation and application support.”

- Advertisement -

This integration builds on Kemin’s decades of enzyme expertise to create a seamless, end-to-end offering to customers. By combining in-house fermentation with advanced formulation, technical sales support, and Customer Laboratory Services, Kemin is uniquely positioned to deliver tailored, high-performing enzyme technologies. These expanded capabilities enhance Kemin’s agility and accelerate innovation, empowering customers to stay ahead in competitive and evolving markets.

- Advertisement -

About Kemin Industries

- Advertisement -

Kemin Industries (www.kemin.com) is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human and animal health and nutrition, pet food, aquaculture, nutraceutical, food technologies, crop technologies, textile, biofuel, and animal vaccine industries.

- Advertisement -

For over half a century, Kemin has been dedicated to using applied science to address industry challenges and offer product solutions to customers in more than 120 countries. Kemin provides ingredients to feed a growing population with its commitment to the quality, safety, and efficacy of food, feed, and health-related products.

- Advertisement -

Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 3,300 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, Egypt, India, Italy, San Marino, Singapore, South Africa, and the United States.

- Advertisement -

Media Contact: 
Diogo Craveiro, Senior Global Manager, Brand and Marketing Communications |
diogo.craveiro@kemin.com, (+1) 515-559-5361

- Advertisement -

© Kemin Industries, Inc. and its group of companies 2025. All rights reserved. ® TM Trademarks of Kemin Industries, Inc., U.S.A.
Certain statements, product labeling and claims may differ by geography or as required by government requirements.

- Advertisement -

Logo – https://mma.prnewswire.com/media/901853/Updated_Kemin_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/kemin-industries-acquires-cj-bio-subsidiary-cj-youtell-biotech-302561784.html

- Advertisement -
Intellipaat Launches Intellipaat School of Technology to Revolutionise Computer Science Education in India
Hyundai Motor Launches “School of Football” Campaign Featuring Boston Dynamics’ Atlas Ahead of FIFA World Cup 2026
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
Sharjah to Host World Congress for Inclusion 2025 — First Time in the Middle East and North African Region
Laigo Bio completes final close of oversubscribed seed financing of 17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
TAGGED:acquiresbiobiotechindustrieskeminnewssubsidiaryyoutell
Share This Article
Facebook Email Print

Kids Video

An Unlikely Friendship – Shadow Puppets and Desert Adventures!
An Unlikely Friendship – Shadow Puppets and Desert Adventures!
Videos
Daily A‑Z English Sentences for Beginners – Easy Everyday Phrases #EnglishLearning #BeginnerEnglish
Daily A‑Z English Sentences for Beginners – Easy Everyday Phrases #EnglishLearning #BeginnerEnglish
Videos
Learn to Count! ‘Magical Forest Counting Journey’ – Preschool Learning | Gujtubes #nurseryrhyme
Learn to Count! ‘Magical Forest Counting Journey’ – Preschool Learning | Gujtubes #nurseryrhyme
Videos
The Great Pet Rescue 🎉 Hours of Chaos, Hamster Hijinks & Best‑Friend Brilliance! #cartoon
The Great Pet Rescue 🎉 Hours of Chaos, Hamster Hijinks & Best‑Friend Brilliance! #cartoon
Videos
Maya’s Bubble‑Gum Sky Adventure – Floating Island Prank! #cartoon #animation #animatedshortfilm
Maya’s Bubble‑Gum Sky Adventure – Floating Island Prank! #cartoon #animation #animatedshortfilm
Videos
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Dassault Systmes CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systmes
Technology

Dassault Systmes CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systmes

GlobeNews Wire
GlobeNews Wire
22/02/2026
Bounteous Launches Claude Code Lab Series in Partnership with Anthropic to Accelerate Responsible AI Adoption
Gensyn Launches Delphi, the AI-Powered Information Market Reshaping the $250 Billion Creator Economy
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet in the treatment of canine mast cell tumors
Krber to acquire majority stake in Stellium to expand supply chain consulting capabilities
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?